Clinical evidence on polymer-based sirolimus and paclitaxel eluting stents

Minerva Cardioangiologica

Volumn 54, Issue 5, 2006, Pages 539-555

  Iijima, R ^a   Mehilli, J ^a   Schomig A ^a   Kastrati, A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Coronary artery disease; Paclitaxel; Restenosis; Sirolimus; Stents; Thrombosis

Indexed keywords

PACLITAXEL; RAPAMYCIN;

BREAST CANCER; CLINICAL ASSESSMENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG BINDING; DRUG ELUTING STENT; DRUG FORMULATION; DRUG MECHANISM; GRAFT REJECTION; HUMAN; META ANALYSIS; OVARY CANCER; PERCUTANEOUS CORONARY INTERVENTION; POLYMER PRODUCTION; PROPHYLAXIS; RESTENOSIS; REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

COMBINED MODALITY THERAPY; CORONARY ARTERIOSCLEROSIS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; POLYMERS; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; STENTS; TUBULIN MODULATORS;

EID: 33750713335     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Schömig A, Kastrati A, Wessely R. Prevention of restenosis by systemic drug therapy: back to the future? Circulation 2005;112:2759-6l.
2. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
3. Schömig A, Kastrati A, Dietz R, Rauch B, Neumann FJ, Katus HH et al. Emergency coronary stenting for dissection during percutaneous transluminal coronary angioplasty: angiographic follow-up after stenting and after repeat angioplasty of the stented segment. J Am Coll Cardiol 1994;25:1053-60.
4. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701-6.
5. Kastrati A, Schühlen H, Schömig A. Stenting for small coronary vessels: a contestable winner. J Am Coll Cardiol 2001;38:1604-7.
6. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med 2003;138:777-86.
7. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KKL et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998;339:1665-71.
8. Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med 1996;334:1084-9.
9. Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004;350:232-8.
10. Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004;110:3627-35.
11. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006;295:1531-8.
12. Kastrati A, Dirschinger J, Boekstegers P, Elezi S, Schühlen H, Pache J et al. Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients. Catheter Cardiovasc Interv 2000;50:290-7.
13. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schühlen H, Neumann FJ et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001;103:2816-21.
14. Kastrati A, Schömig A, Dirschinger J, Mehilli J, von Welser N, Pache J et al. Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. Circulation 2000;101:2478-83.
15. Pache J, Kastrati A, Mehilli J, Schühlen H, Dotzer F, Hausleiter J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003;41:1283-8.
16. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stem implantation. J Am Coll Cardiol 1998;32:584-9.
17. Bauters C, Hubert E, Prat A, Bougrimi K, Van Belle E, McFadden EP et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol 1998;31:1291-8.
18. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schömig A. Vessel size and long-term outcome after coronary stent placement. Circulation 1998;98:1875-80.
19. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866-73.
20. Elezi S, Kastrati A, Wehinger A, Walter H, Schühlen H, Hadamitzky M et al. Clinical and angiographic outcome after stent placement for chronic coronary occlusion. Am J Cardiol 1998;82:803-6.
21. Kastrati A, Elezi S, Dirschinger J, Hadamitzky M, Neumann FJ, Schömig A. Influence of lesion length on restenosis after coronary stent placement. Am J Cardiol 1999;83:1617-22.
22. Kastrati A, Schömig A, Elezi S, Dirschinger J, Mehilli J, Schühlen H et al. Prognostic value of the modified American College of Cardiology/American Heart Association stenosis morphology classification for longterm angiographic and clinical outcome after coronary stent placement. Circulation 1999;100:1285-90.
23. Kastrati A, Schömig A, Elezi S, Schühlen H, Dirschinger J, Hadamitzky M et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997;30:1428-36.
24. Kastrati A, Dirschinger J, Schömig A. Genetic risk factors and restenosis after percutaneous coronary interventions. Herz 2000;25:34-46.
25. Edelman ER, Rogers C. Pathobiologic responses to stenting. Am J Cardiol 1998;81(7A):4E-6E.
26. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005;111:2257-73.
27. Farb A, Kolodgie FD, Hwang JY, Burke AP, Tefera K, Weber DK et al. Extracellular matrix changes in stented human coronary arteries. Circulation 2004;110:940-7.
28. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224-30.
29. Rectenwald JE, Moldawer LL, Huber TS, Seeger JM, Ozaki CK. Direct evidence for cytokine involvement in neointimal hyperpiasia. Circulation 2000;102:1697-702.
30. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
31. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
32. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
33. Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzenstaller T et al. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J 2005;26:1475-81.
34. Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006;113:273-9.
35. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006;114:798-806.
36. Elezi S, Dibra A, Schömig A, Kastrati A. Current drug-eluting stents in complex patients and lesions. Minerva Cardioangiol 2006;54:5-22.
37. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part I. Circulation 2002;106:2734-40.
38. Regar E, Sianos G, Serruys PW. Stent development and local drug delivery. Br Med Bull 2001;59:227-48.
39. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-5.
40. Vasquez EM. Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health Syst Pharm 2000;57:437-48; quiz 449-51.
41. Wessely R, Schömig A, Kastrati A. Sirolimus and paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol 2006;47:708-14.
42. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 1998;98:82-9.
43. Boehm M, Nabel EG. Cell cycle and cell migration: new pieces to the puzzle. Circulation 2001;103:2879-81.
44. Morgan DO. Principles of CDK regulation. Nature 1995;374:131-4.
45. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12.
46. Sun J, Marx SO, Chen HJ, Poon M, Marks AR, Rabbani LE. Role for p27(Kip1) in vascular smooth muscle cell migration. Circulation 2001;103:2967-72.
47. Tanner FC, Yang ZY, Duckers E, Gordon D, Nabel GJ, Nabel EG. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ Res 1998;82:396-403.
48. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996;98:2277-83.
49. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994;78:35-43.
50. Nicolaou KC, Yang Z, Liu JJ, Ueno H, Nantermet PG, Guy RK et al. Total synthesis of taxol. Nature 1994;367:630-4.
51. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-14.
52. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003;3:193-203.
53. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-45.
54. Giannakakou P, Robey R, Fojo T, Blagosklonny MV. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 2001;20:3806-13.
55. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000;88:2619-28.
56. Curfman GD. Sirolimus-eluting coronary stents. N Engl J Med 2002;346:1770-1.
57. Chieffo A, Colombo A. Polymer-based paclitaxel-eluting coronary stents. Clinical results in de novo lesions. Herz 2004;29:147-51.
58. Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 2001;104:600-5.
59. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005;366:921-9.
60. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-5.
61. Chan C, Zambahari R, Kaul U, Cohen SA, Buchbinder M, Investigators obotDS. Outcomes in diabetic patients with multivessel disease and long lesions: results from the DECODE STUDY, http://www.tctmd.com/csportal/appmanager/tctmd/ main?_nfpb=true&_pageLabel=TCT MDContent&hdCon=1382193.
62. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, Gomez-Hospital JA, Alfonso F, Hernandez-Antolin R et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005;112:2175-83.
63. Schofer J, Schlüter M, Gershlick AH, Wijns W, Garcia E, Schampaert E et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
64. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary instent restenosis: a randomized controlled trial. JAMA 2005;293:165-71.
65. Pache J, Dibra A, Mehilli J, Dirschinger J, Schömig A, Kastrati A. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J 2005;26:1262-8.
66. Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 2006;114:921-8.
67. Alfonso F, Perez-Vizcayno MJ, Hernandez R, Bethencourt A, Marti V, Lopez-Minguez JR et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol 2006;47:2152-60.
68. Kelbaek H, Thuesen L, Helqvist S, Klovgaard L, Jorgensen E, Aljabbari S et al. The Stenting Coronary Arteries in Non-stress/benestent Disease (SCAND-STENT) trial. J Am Coll Cardiol 2006;47:449-55.
69. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A et al. Sirolimus-eluting isuncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004;292:2727-34.
70. Holmes DR Jr, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA 2006;295:1264-73.
71. Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005;293:2109-17.
72. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006;55:1093-104.
73. Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 2005;111:1040-4.
74. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;55:1105-13.
75. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
76. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
77. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005;112:3306-13.
78. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294:1215-23.
79. Stone GW, Ellis SG, O'Shaughnessy CD, Martin SL, Satler L, McGarry T et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 2006;295:1253-63.
80. Lansky AJ, Roubin GS, O'Shaughnessy CD, Moore PB, Dean LS, Raizner AE et al. Randomized comparison of GR-II stent and Palmaz-Schatz stent for elective treatment of coronary stenoses. Circulation 2000;102:1364-8.
81. Kastrati A, Mehilli J, Dirschinger J, Pache J, Ulm K, Schühlen H et al. Restenosis after coronary placement of various stent types. Am J Cardiol 2001;87:34-9.
82. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
83. Boersma E. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006;27:779-88.
84. Every NR, Parsons LS, Hlatky M, Martin JS, Weaver WD. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. Myocardial Infarction Triage and Intervention Investigators. N Engl J Med 1996;335:1253-60.
85. Edelman ER, Rogers C. Stent-versus-stent equivalency trials: are some stents more equal than others? Circulation 1999;100:896-8.
86. Hausleiter J, Kastrati A, Mehilli J, Schühlen H, Pache J, Dotzer F et al. Lesion complexity makes differences in stent performance evident: lessons from the randomized ISAR-STEREO trial. Eur Heart J 2002;4(Suppl):307.
87. Rogers C, Edelman ER. Pushing drug-eluting stents into uncharted territory: simpler than you think-more complex than you imagine. Circulation 2006;113:2262-5.
88. de Lezo J, Medina A, Pan M, Romero M, Delgado A, Segura J et al. Drug-eluting stents for complex lesions: randomized rapamycin versus paclitaxel CORPAL study. J Am Coll Cardiol 2005;45:75A.
89. Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-70.
90. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006;295:895-904.
91. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653-62.
92. Goy JJ, Stauffer JC, Siegenthaler M, Benoit A, Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXI trial. J Am Coll Cardiol 2005;45:308-11.
93. Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schömig A. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006;27:260-6.
94. Hong MK, for the Long-DBS II Study investigators. Percutaneous treatment of long native coronary lesions with drug-eluting stent-II: Cypher versus Taxus. Presented at the American College of Cardiology Scientific Sessions, 2006, March 12-15, Atlanta, GA.
95. Lee JH, Kim HS, Lee SW, Park JH, Choi SW, Jeong JO, et al. Prospective randomized trial of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction. Presented at the American College of Cardiology Scientific Sessions, 2006, March 12-15, Atlanta, GA.
96. Kastrati A, Dibra A, Eberle S, Mehilli J, Suarez de Lezo J, Goy JJ et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 2005;294:819-25.
97. Elezi S, Dibra A, Folkerts LJ, Mehilli J, Heigl S, Schömig A et al. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease. J Am Coll Cardiol 2006;48:262-7.
98. Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schömig A et al. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol. In press.
99. Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 2006;113:2293-300.
100. COMBAT trial: Comparison of bypass surgery versus angioplasty using sirolimus-eluting stent in patients with left main coronary artery disease. http:// tct2005.com/mainarena/tue/leon.swf
101. Kastrati A, Schömig A, Dietz R, Neumann FJ, Richardt G. Time course of restenosis during the first year after emergency coronary stenting. Circulation 1993;87: 1498-505.
102. Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, Sawada Y et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med 1996;334:561-6.
103. Wessely R, Kastrati A, Schömig A. Late restenosis in patients receiving a polymer coated sirolimus-eluting stent. Ann Int Med 2005;143:392-4.
104. Sousa JE, Costa MA, Abizaid A, Feres F, Seixas AC, Tanajura LF et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation 2005;111:2326-9.
105. Aoki J, Colombo A, Dudek D, Banning AP, Drzewiecki J, Zmudka K et al. Peristent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation 2005;112:3876-83.
106. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
107. Camenzind E. Safety of drug-eluting stents: insights from meta analysis. http://www.escardio.org/knowledge/congresses/CongressReports/hotlinesandctus/ 707009_Camenzind.htm.
108. von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Schömig A. A double-blind randomized comparison between two different clopidogrel maintenance doses after percutaneous coronary intervention (ISAR-CHOICE 2 Trial). Presented at the Congress of the European Society of Cardiology, 2006, September 2-6, Barcelona, Spain.
109. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366-73.
110. Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A et al. Mechanism of late instent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002;106:2649-51.
111. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-5.
112. Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S et al. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol 2005;25:748-53.